Spots Global Cancer Trial Database for Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer
Official Title: A Phase 1 Open Label Dose Ranging Study of Oral RH324 in Advanced Non-Small Cell Lung Cancer
Study ID: NCT05580172
Conditions
Interventions
Study Description
Brief Summary: Phase 1 open label dose ranging study of RH324 in advanced non-small cell lung cancer
Detailed Description: This is a Phase 1 open label dose ranging study to assess the safety and tolerability of oral RH324 in advanced non-small cell lung cancer
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Case Comprehensive Cancer Center University Hospitals, Cleveland, Ohio, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
